Biomarkers of Broccoli Intake: A Pilot Study
1 other identifier
interventional
6
1 country
1
Brief Summary
The objectives of the study are 1) to characterize plasma and urinary metabolites that originate from glucobrassicin, 1-methoxyglucobrassicin, 4-methoxyglucobrassicin, and 4-hydroxyglucobrassicin, which are the major indole glucosinolates found in broccoli, and 2) to identify novel plasma and urinary metabolites following broccoli consumption that may have roles in reducing the risk of cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable healthy-volunteers
Started Nov 2017
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 15, 2017
CompletedFirst Posted
Study publicly available on registry
September 19, 2017
CompletedStudy Start
First participant enrolled
November 6, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 17, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
November 17, 2017
CompletedNovember 21, 2017
November 1, 2017
11 days
September 15, 2017
November 20, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
The change in glucosinolate metabolites will be measured in blood plasma and urine.
To track the changes of indole glucosinolate metabolites, glucosinolate metabolites will be measured in both blood plasma and urine.
On Day 11
Study Arms (1)
Broccoli
EXPERIMENTALSubjects will consume a dose of broccoli on day 11
Interventions
Eligibility Criteria
You may qualify if:
- Non tobacco user
- Cancer Free
- Not currently taking glucosinolate/isothiocyanate containing supplements
You may not qualify if:
- Type 2 diabetes requiring the use of diabetes pills, insulin, or non-insulin shots
- Use of blood-thinning medications such as Coumadin (warfarin), Dicumarol, or Miradon (anisindione)
- History of bariatric surgery or nutrient malabsorption disease (such as celiac disease) or other metabolic disorders requiring special diet recommendations
- Pregnant, lactating, or intending to become pregnant during the study period
- Crohn's disease or diverticulitis
- Suspected or known strictures, fistulas or physiological/mechanical GI obstruction
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
USDA-ARS, Beltsville Human Nutrition Research Center
Beltsville, Maryland, 20705, United States
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- FED
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Research Molecular Biologist
Study Record Dates
First Submitted
September 15, 2017
First Posted
September 19, 2017
Study Start
November 6, 2017
Primary Completion
November 17, 2017
Study Completion
November 17, 2017
Last Updated
November 21, 2017
Record last verified: 2017-11
Data Sharing
- IPD Sharing
- Will not share